TABLE 1.
Evaluation of phage specificity with various bacteria
| Bacterial isolate(s) | Serotype | Reference(s) | Plaque
formation
|
Lytic efficiency of phage mixture
ata:
|
||||
|---|---|---|---|---|---|---|---|---|
| KH1 | KH4 | KH5 | 37°C
|
4°Cb | ||||
| Aerated | Nonaerated | |||||||
| E. coli isolates | ||||||||
| ATCC 43894 | O157:H7 | 12, 39 | + | + | + | + | − | + |
| ATCC 43890 | O157:H7 | 12 | + | + | + | + | − | + |
| ATCC 43889 | O157:H7 | 12, 23 | + | + | + | + | − | + |
| ATCC 43888 | O157:H7 | 12 | + | + | + | + | − | + |
| A-9 | O157:H7 | 20 | + | + | + | + | − | + |
| G-13 | O157:H7 | 20 | + | + | + | + | − | + |
| I-1 | O157:H7 | 20 | + | + | + | + | − | + |
| FDA 13A81 | O157:H16 | 9 | + | + | + | + | − | + |
| FDA 13A82 | O157:H16 | 9 | + | + | + | + | − | + |
| CDC 3005-89 | O157:H38 | 9 | + | + | + | + | − | + |
| FDA 13A83 | O157:H45 | 9 | + | + | + | + | − | + |
| CDC 3004-89 | O157:H3 | 9 | − | − | − | + | − | + |
| CDC G5933 | O157:H12 | 9 | − | − | − | + | − | + |
| FDA 13A80 | O157:H16 | 9 | − | − | − | + | − | + |
| 7A, 7C, 7D, 7E | O157:H43 | 9 | − | − | − | + | − | + |
| 5A, 5B, 5C, 5D, 5E | O55:H7 | 9 | − | − | − | − | − | − |
| Enteropathogenic isolatesc | 10 | − | − | − | − | − | − | |
| 3812-3 | O5:NMd | 20 | − | − | − | − | − | − |
| Other species | ||||||||
| Yersinia enterocolitica | O9 | 12, 38 | − | − | − | − | − | − |
| Citrobacter freundii | NAe | 12 | − | − | − | − | − | − |
| Vibrio cholerae 569B | O1 | 12, 38 | − | − | − | − | − | − |
| Vibrio cholerae O395 | O1 | 12, 38 | − | − | − | − | − | − |
a
The MOI was 103 PFU/CFU.
b
Data for aerated and nonaerated cultures.
c
A total of 33 different enteropathogenic E. coli isolates of assorted serotypes were tested. The serotypes included ON:HN, O8:H41, O12:NM, O15:HN, O18:HN, O23:H15, O25:H2, O26:H2, O26:HN, O26:NM, O46:HN, O55:H7, O66:HN, O75:HN, O85:NM, O86:H34, O96:HN, O103:H6, O111:HN, O115:NM, O118:H8, O125:H6, O127:H40, O128:H2, O131:HN, O145:HN, O153:HN, and O156:H8.
d
NM, nonmotile.
e
NA, not applicable.